Opportunity ID: 271352

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-MH-16-220
Funding Opportunity Title: Novel Assays to Address Translational Gaps in Treatment Development (UH2/UH3)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.242 — Mental Health Research Grants
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Jan 12, 2015
Last Updated Date:
Original Closing Date for Applications: Apr 03, 2015
Current Closing Date for Applications: Apr 03, 2015
Archive Date: May 04, 2015
Estimated Total Program Funding: $1,500,000
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Small businesses
For profit organizations other than small businesses
Native American tribal governments (Federally recognized)
State governments
Special district governments
Public and State controlled institutions of higher education
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
County governments
City or township governments
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
Independent school districts
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Additional Information

Agency Name: National Institutes of Health
Description: The overall goal of this initiative is to identify, optimize, and evaluate measures of neurophysiological processes that are disrupted within or across mental disorders and which can be assessed in animals and humans. The goal is to support further development of these measures as assays for evaluating potential new drug and device therapies and their targets. Data will also reveal assay measures where the performance between preclinical species and humans is dissimilar, thus establishing a firm basis for limiting speculative extrapolations of preclinical findings. Ultimately, the goal of this FOA is to improve the efficiency of the therapeutic development process by addressing inconsistencies between the preclinical screening pipeline and clinical evaluation of new treatment candidates and thereby hasten the development of more effective treatments for mental disorders.

The objectives of the FOA will be accomplished by supporting partnerships among basic and translational neuroscientists who are committed to advancing the discovery of physiological measures as tools for target validation and therapeutic development. Groups will be tasked with building a target-engagement-linked-to-functional-brain-effect suite of assays with potential to translate from animals to humans and thus serve as a basis for selecting preclinical treatment candidates for further development and clinical testing. Towards this goal, the FOA will support development, optimization and evaluation of brain based assays in both preclinical species and in healthy humans and the evaluation of assay performance in response to carefully selected chemical, physiological, or behavioral manipulations.

Link to Additional Information: http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-16-220.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV

Email:FBOWebmaster@OD.NIH.GOV

Version History

Version Modification Description Updated Date

Related Documents

Packages

Agency Contact Information: NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV

Email: FBOWebmaster@OD.NIH.GOV

Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
FORMS-C FORMS-C PKG00211624 Mar 03, 2015 Apr 03, 2015 View

Package 1

Mandatory forms

271352 RR_SF424_2_0-2.0.pdf

271352 PHS398_ResearchPlan_2_0-2.0.pdf

271352 PHS398_CoverPageSupplement_2_0-2.0.pdf

271352 RR_Budget_1_3-1.3.pdf

271352 RR_KeyPersonExpanded_2_0-2.0.pdf

271352 RR_OtherProjectInfo_1_3-1.3.pdf

271352 PerformanceSite_2_0-2.0.pdf

Optional forms

271352 PlannedReport-1.0.pdf

271352 PHS398_CumulativeInclusionReport-1.0.pdf

271352 RR_SubawardBudget30_1_3-1.3.pdf

2025-07-09T08:27:55-05:00

Share This Post, Choose Your Platform!

About the Author: